Log in

NASDAQ:ONCSOncoSec Medical Stock Price, Forecast & News

$2.49
+0.10 (+4.18 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.36
Now: $2.49
$2.57
50-Day Range
$1.48
MA: $1.74
$2.39
52-Week Range
$1.04
Now: $2.49
$3.01
Volume263,385 shs
Average Volume241,090 shs
Market Capitalization$56.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (PISCES/KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (OMS-141/KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company has completed Phase I neoadjuvant clinical trial of ImmunoPulse IL-12 in combination with an anti-PD-1 in surgically resectable melanoma. Additionally, it is developing new DNA-encoded therapeutic candidates and tumor indications. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the PISCES/KEYNOTE-695 and OMS-141/KEYNOTE-890 studies; a collaboration with the GOG Foundation, Inc. to conduct a registration-enabled study of tavokinogene telseplasmid in women with recurrent/persistent cervical cancer; and a collaborative research agreement with Duke University School of Medicine in HER2+ breast cancer. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Read More
OncoSec Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCS
CUSIPN/A
Phone855-662-6732

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.28 per share

Profitability

Net Income$-30,280,000.00

Miscellaneous

Employees33
Market Cap$56.65 million
Next Earnings Date6/12/2020 (Estimated)
OptionableNot Optionable

Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter.

OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

How has OncoSec Medical's stock been impacted by COVID-19 (Coronavirus)?

OncoSec Medical's stock was trading at $1.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ONCS shares have increased by 81.8% and is now trading at $2.49. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of OncoSec Medical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OncoSec Medical.

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release its next quarterly earnings announcement on Friday, June 12th 2020. View our earnings forecast for OncoSec Medical.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Inc (NASDAQ:ONCS) released its quarterly earnings results on Wednesday, October, 25th. The biotechnology company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($2.30) by $0.50. View OncoSec Medical's earnings history.

When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work?

Shares of OncoSec Medical reverse split on the morning of Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ONCS?

1 brokerages have issued twelve-month target prices for OncoSec Medical's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate OncoSec Medical's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 141.0% from the stock's current price. View analysts' price targets for OncoSec Medical.

What are Wall Street analysts saying about OncoSec Medical stock?

Here are some recent quotes from research analysts about OncoSec Medical stock:
  • 1. According to Zacks Investment Research, "OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in San Diego, California. " (12/31/2019)
  • 2. Maxim Group analysts commented, "OncoSec announced a collaboration agreement with Dana-Farber Cancer Institute whereby OncoSec acquired an exclusive option to licensing rights to CAR-T candidates and associated IP from research being conducted the Marasco Laboratory." (6/28/2019)

Has OncoSec Medical been receiving favorable news coverage?

News headlines about ONCS stock have been trending extremely negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OncoSec Medical earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutOncoSec Medical.

Are investors shorting OncoSec Medical?

OncoSec Medical saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 220,200 shares, an increase of 16.9% from the April 30th total of 188,300 shares. Based on an average daily trading volume, of 248,000 shares, the short-interest ratio is presently 0.9 days. Currently, 2.5% of the shares of the stock are short sold. View OncoSec Medical's Current Options Chain.

Who are some of OncoSec Medical's key competitors?

What other stocks do shareholders of OncoSec Medical own?

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the following people:
  • Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
  • Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 55)
  • Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 39)
  • Ms. Sara M. Bonstein, CFO, COO & Company Sec. (Age 38)
  • Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Sigma Planning Corp (0.12%). Company insiders that own OncoSec Medical stock include Alpha Holdings, Inc, Avtar S Dhillon, Daniel J O'connor, James M Demesa, Punit Dhillon, Richard B Slansky and Sara Bonstein. View institutional ownership trends for OncoSec Medical.

Which institutional investors are buying OncoSec Medical stock?

ONCS stock was purchased by a variety of institutional investors in the last quarter, including Sigma Planning Corp. Company insiders that have bought OncoSec Medical stock in the last two years include Alpha Holdings, Inc, Daniel J O'connor, and James M Demesa. View insider buying and selling activity for OncoSec Medical.

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $2.49.

How big of a company is OncoSec Medical?

OncoSec Medical has a market capitalization of $56.65 million. OncoSec Medical employs 33 workers across the globe.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is www.oncosec.com.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.